FTC Takes Aim at Enbrel Patents as Moderna Slides 5.26%
An FTC challenge to Amgen's Enbrel patent wall lands the same day Moderna drops 5.26%, with the Merck-partnered cancer vaccine still years from a finish line and Lady Gaga entering biotech.
The Federal Trade Commission is challenging Amgen's patent strategy around its long-running arthritis drug Enbrel, while Moderna shares fell 5.26% to $137.50 as of 15:21 GMT on Aug. 24, 2026, amid continued questions over the timeline for its cancer vaccine partnered with Merck.
Three biotech storylines converged on Monday, and only one of them involves a pop star. The Federal Trade Commission has opened a challenge to the patent strategy that Amgen (AMGN) has built around Enbrel, the etanercept injection that has been one of the industry's most durable revenue engines. Separately, the cancer vaccine that Moderna (MRNA) and Merck (MRK) have been developing together remains on what STAT News describes as a long and winding path. And Lady Gaga and her fianc\, adding a celebrity name to a sector that has spent two years scrapping for capital.
The market read the day unevenly. Amgen traded at 440.36 as of 15:21 GMT on Aug. 24, 2026, up 0.23% from a prior close of 439.33 \u2014 the FTC news, at least in the first hours, was not treated as an existential threat. Moderna was the day's damage: 137.50, down 5.26% from 145.13, with an intraday range stretching from 130.00 to 145.50. Merck slipped 1.51% to 150.25.
Why a patent thicket around Enbrel draws regulators
Enbrel is the archetype of what critics call a patent thicket: a biologic whose core composition protection expired long ago but which remains shielded by later-filed patents covering formulation, manufacturing and method of use. The practical effect in the United States has been that biosimilar versions approved by the FDA have sat on the shelf, unlaunched, while the branded product kept its price and its market.
An FTC challenge attacks that structure rather than any single patent. The agency's theory in cases like this is that layering secondary patents to extend exclusivity past the point the original invention justified is a competition problem, not merely a patent-law question. That reframing matters because it moves the fight out of district court patent litigation, where Amgen has historically done well, and into an antitrust posture where the remedy could be behavioral \u2014 constraints on how the company enforces or lists its patents.
For Amgen, Enbrel is a legacy franchise, not a growth story. The company has spent years building out newer products precisely because this revenue line was always going to face an ending. The question the FTC action raises is whether that ending arrives sooner and more abruptly than the company's planning assumed. Investors on Monday were not pricing an abrupt outcome; a 0.23% gain on the day is noise, and the shares traded within a 435.51 to 441.89 band.
Moderna's 5.26% drop and the vaccine that keeps not arriving
The Moderna-Merck individualized neoantigen therapy \u2014 a cancer vaccine tailored to the mutations in a specific patient's tumor \u2014 has been the most-watched asset in personalized oncology for several years. It is also a reminder of how differently biotech timelines run from investor patience. Manufacturing a bespoke product for each patient, running randomized trials long enough to show survival benefit, and then convincing regulators and payers that the whole apparatus is scalable is a multi-year proposition even when everything works.
Monday's 5.26% decline took Moderna well below its prior close, and the intraday spread between 130.00 and 145.50 is unusually wide \u2014 a range of that size in a single session signals a market with no settled view on the name. Against benchmarks that were only modestly lower, the move was company-specific: the S&P 500 tracker was at $762.53, off 0.42%, and the Nasdaq 100 tracker at $705.16, down 1.16%, while the Dow tracker edged up 0.11% to $532.82.
Merck's smaller 1.51% slide reflects the asymmetry of the partnership. For Merck, the vaccine is one program inside a very large oncology portfolio. For Moderna, it is one of the few remaining reasons to believe the mRNA platform extends beyond infectious disease. That difference in exposure is visible in the tape.
What a celebrity founder actually changes
For Moderna, it is one of the few remaining reasons to believe the mRNA platform extends beyond infectious disease.
Lady Gaga and her fianc\u00e9 launching a biotech venture will draw attention disproportionate to the size of whatever they build. Celebrity-backed health companies have a mixed record; the ones that endure tend to be those where the famous name opens doors to capital and patient communities without touching the science. The ones that fail are usually the reverse.
What the launch does signal is that biotech remains a destination for outside capital even after a prolonged funding drought. New money entering the sector \u2014 from any source \u2014 is a marginal positive for a startup ecosystem that has been consolidating, cutting headcount and folding programs. Whether this particular venture matters will depend entirely on what it works on and who it hires, neither of which is yet clear.
What to track from here
On the Amgen side, the milestones are procedural before they are financial: how the FTC frames its complaint, whether the company seeks a settlement, and whether any biosimilar sponsor moves to launch on the strength of the challenge. Nothing about Monday's share price suggests the market expects near-term revenue disruption, but antitrust matters compound slowly and then land at once.
On Moderna, the readthrough is simpler. The stock is trading as a binary on pipeline delivery. Each stretch of the cancer vaccine's timeline without a definitive readout costs the company credibility it can no longer easily replace, and a 5.26% single-day move on process news rather than data is evidence of how thin the confidence layer has become.
The connective tissue across all three items is the same pressure: the industry's oldest revenue streams are being defended in court, its newest ones are taking longer than promised, and capital is looking for new entry points. That is a sector working through a transition, not a sector in retreat \u2014 but the transition is being paid for in share price volatility, and Monday supplied a clear example.
Key facts
- Moderna (MRNA): 137.50, -5.26% as of 15:21 GMT, Aug. 24, 2026
- Amgen (AMGN): 440.36, +0.23% as of 15:21 GMT, Aug. 24, 2026
- Merck (MRK): 150.25, -1.51% as of 15:21 GMT, Aug. 24, 2026
- Regulatory action: FTC challenging Amgen's Enbrel patent strategy
Frequently asked questions
What is the FTC challenging about Enbrel?
The Federal Trade Commission is challenging Amgen's patent strategy surrounding Enbrel, its long-established etanercept treatment. Such challenges typically target the practice of layering secondary patents covering formulation, manufacturing or method of use to extend exclusivity well beyond the original composition patent, which can keep approved biosimilar competitors from launching in the United States.
How did Amgen shares react to the FTC news?
Amgen was essentially flat. As of 15:21 GMT on Aug. 24, 2026, the shares traded at 440.36, up 0.23% from a prior close of 439.33, within a day range of 435.51 to 441.89. That muted response suggests investors did not treat the antitrust challenge as an immediate threat to near-term Enbrel revenue.
Why did Moderna fall more than 5% on Aug. 24, 2026?
Moderna traded at 137.50, down 5.26% from a prior close of 145.13, with an intraday range from 130.00 to 145.50. The decline coincided with renewed attention to the extended development timeline for the individualized cancer vaccine it is developing with Merck, an asset central to the case for its mRNA platform beyond infectious disease.
What is the Moderna-Merck cancer vaccine?
It is an individualized neoantigen therapy, a cancer vaccine designed against the specific mutations found in an individual patient's tumor rather than a single fixed formulation. Bespoke manufacturing per patient, plus the long randomized trials required to demonstrate survival benefit, make the development path considerably slower than for conventional drugs.
Why did Merck fall less than Moderna on the same news?
Merck slipped 1.51% to 150.25 while Moderna dropped 5.26%. The gap reflects exposure. The cancer vaccine is one program within Merck's very large oncology portfolio, whereas for Moderna it represents one of the most important remaining demonstrations that its mRNA technology can work outside infectious disease.
What is Lady Gaga's biotech venture?
Lady Gaga and her fianc\u00e9 are launching a biotech startup, according to reporting by STAT News. Details of the company's scientific focus, backers and leadership have not been specified. Celebrity-founded health ventures have a mixed track record, with the more durable ones typically using the founder's profile for capital access rather than scientific direction.
Sources
Photo: olia danilevich · Pexels Licence — source
